Abvc biopharma secures $200,000 in first cash licensing payment from oncology products partner, totaling $546,000 from three partners

Fremont, calif., dec. 11, 2024 (globe newswire) -- abvc biopharma, inc. (nasdaq: abvc), a clinical-stage biopharmaceutical company advancing therapeutic solutions in ophthalmology, cns (central nervous system), and oncology/hematology, announced the receipt of a $200,000 cash payment from oncox biopharma inc. ("oncox") as part of its strategic licensing agreement for certain oncology-related products; this payment marks the first installment of $5 million in potential licensing fees from oncox. with this payment, the total accumulated cash payment abvc has received from its three strategic partners for licensing various abvc products is $546,000. abvc and its subsidiaries biolite inc. and rgene corporation are each eligible to receive up to 10m oncox shares, $5m cash payment, and royalties up to $50m after the product launches.1
ABVC Ratings Summary
ABVC Quant Ranking